NVO Financials: Novo Nordisk A/S AI Analysis

Home

Stock

NVO

Financials

NVO Financial

Novo Nordisk A/S

$36.41

-1.27%

$-0.47

As of today:Mar 25, 15:29:16 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$36.89

Open

$37.15

Day's Range

$36.36 - $37.39

52 week range

$35.85 - $81.44

Volume

11.8M

Avg.Volume

24.2M

Dividend yield

EPS (TTM)

3.62

Market Cap

$122.7B

What is Novo Nordisk A/S?

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

NVO Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	309,064	309,064	290,403	232,261	176,954	140,800
Revenue Growth (YoY)	6%	6%	25%	31%	26%	11%
Cost of Revenue	58,788	58,788	43,560	35,765	28,448	23,658
Gross Profit	250,276	250,276	246,843	196,496	148,506	117,142
Selling, General & Admin	70,279	70,279	66,546	60,767	49,932	40,409
Research & Development	52,039	52,039	38,021	29,373	21,761	16,292
Operating Expenses	122,618	122,618	107,942	91,798	72,837	57,784
Other Non Operating Income (Expenses)	--	--	-289	-197	-181	-122
Pretax Income	130,540	130,540	127,191	104,674	69,062	59,080
Income Tax Expense	28,106	28,106	26,203	20,991	13,537	11,323
Net Income	102,434	102,434	100,988	83,683	55,525	47,757
Net Income Growth	1%	1%	21%	51%	16%	13%
Shares Outstanding (Diluted)	4,452.15	4,447.85	4,463	4,494.8	4,544.6	4,606.2
Shares Change (YoY)	0%	0%	-1%	-1%	-1%	-2%
EPS (Diluted)	23	23.03	22.63	18.62	12.22	10.37
EPS Growth	1%	2%	22%	52%	18%	15%
Free Cash Flow	28,989	28,989	69,659	70,012	64,134	47,615
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	80.97%	80.97%	85%	84.6%	83.92%	83.19%
Operating Margin	41.3%	41.3%	47.83%	45.07%	42.76%	42.15%
Profit Margin	33.14%	33.14%	34.77%	36.02%	31.37%	33.91%
Free Cash Flow Margin	9.37%	9.37%	23.98%	30.14%	36.24%	33.81%
EBITDA	149,640	149,640	158,008	114,111	83,031	65,383
EBITDA Margin	48.41%	48.41%	54.4%	49.13%	46.92%	46.43%
D&A For EBITDA	21,982	21,982	19,107	9,413	7,362	6,025
EBIT	127,658	127,658	138,901	104,698	75,669	59,358
EBIT Margin	41.3%	41.3%	47.83%	45.07%	42.76%	42.15%
Effective Tax Rate	21.53%	21.53%	20.6%	20.05%	19.6%	19.16%

Follow-Up Questions

What are Novo Nordisk A/S's key financial statements?



According to the latest financial statement (Form-10K), Novo Nordisk A/S has a total asset of $542,902, Net profit of $102,434

What are the key financial ratios for NVO?



Novo Nordisk A/S's Current ratio is 1.55, has a Net margin is 33.14, sales per share of $69.48.

How is Novo Nordisk A/S's revenue broken down by segment or geography?



Novo Nordisk A/S largest revenue segment is Victoza, at a revenue of 3,020,000,000 in the most earnings release.For geography, US Revenue is the primary market for Novo Nordisk A/S, at a revenue of 173,166,000,000.

Is Novo Nordisk A/S profitable?



yes, according to the latest financial statements, Novo Nordisk A/S has a net profit of $102,434

Does Novo Nordisk A/S have any liabilities?



yes, Novo Nordisk A/S has liability of 348,855

How many outstanding shares for Novo Nordisk A/S?



Novo Nordisk A/S has a total outstanding shares of 4,439.05

Novo Nordisk A/S (NVO) Financial

NVO Stock Price Chart